Recruiting

NCT Number: NCT00177268

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cutaneous T-Cell Lymphoma Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Eczema Genetic Diseases, Inborn Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, T-Cell, Cutaneous Lymphoproliferative Disorders Mycosis Fungoides Neoplasms Neoplasms by Histologic Type Sezary Syndrome Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

Location status: Recruiting

Location contact

Charity L Ruhl, LPN

CONTACT

[email protected]

4126472013

Hassane Zarour, MD

SUB_INVESTIGATOR

Louis Falo, M.D., Ph.D.

SUB_INVESTIGATOR

Nicolena Verardi, PA-C

SUB_INVESTIGATOR

Oleg Akilov, MD, PhD

CONTACT

[email protected]

412-647-4200

Oleg E. Akilov, MD, Ph.D

PRINCIPAL_INVESTIGATOR

Patrizia Fuschiotti, PhD

SUB_INVESTIGATOR

About this study

The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor:

immunologic assays/flow cytometry
tumor progression/regression
genomic studies
proteomic studies
others germane to the advancement of CTCL treatment

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 or older
able and willing to provide informed consent
diagnosed with CTCL
diagnosed with either atopic dermatitis or eczema

Exclusion criteria

Lack of CTCL, atopic dermatitis, or eczema diagnosis in medical record

Treatment and study plan

Blood draw, skin biopsy or urine collection

Other

Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.

Primary outcomes

Proteomics of Cutaneous T-cell lymphoma

Time frame: Ongoing

Proteomic variables will be measured in blood and tissue of consented CTCL patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Charity L Ruhl, LPN

CONTACT

[email protected]

4126472013

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Official study title

Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Important dates

Study start: 2004
Primary completion: 2030
Study completion: 2032
First posted: Sep 15, 2005
Registry last updated: Dec 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed